Watch Live

Tweet TWEET

Companies Taking Strategic Initiatives in Delivering Innovative Solutions to Boost Sales and Meet Customer Demands - Research

 Companies Taking Strategic Initiatives in Delivering Innovative Solutions to
   Boost Sales and Meet Customer Demands - Research Report on ResMed, Quest
               Diagnostics, Mettler-Toledo, Gilead, and TearLab

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 7, 2013

NEW YORK, June 7, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting ResMed
Inc. (NYSE: RMD), Quest Diagnostics Inc. (NYSE: DGX), Mettler-Toledo
International, Inc. (NYSE: MTD), Gilead Sciences, Inc. (NASDAQ: GILD), and
TearLab Corporation (NASDAQ: TEAR). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

ResMed Inc. Research Report

On June 3, 2013, ResMed Inc. (ResMed) launched the SleepSeeker Online Tool to
increase patient engagement in therapy for sleep-disordered breathing. "We
know that patient engagement can be a powerful force in improving compliance,"
said Susan de la Torre, Director, Channel Marketing for ResMed. She added,
"SleepSeeker engages patients by providing encouragement and motivation to
learn about their therapy and gives them the tools to become their own health
advocates." SleepSeeker was introduced at "SLEEP 2013", the annual meeting of
the Associated Professional Sleep Societies held in the first week of June
2013. The Full Research Report on ResMed Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at [http://www.wsreports.com/r/full_research_report/ba41_RMD]

--

Quest Diagnostics Inc. Research Report

On May 16, 2013, Quest Diagnostics Inc. (Quest) announced that it has acquired
the toxicology and clinical laboratory business of medical center operator
Concentra, a subsidiary of Humana Inc. In addition, Quest Diagnostics has
entered into a long-term agreement with Concentra to be its primary provider
of workplace drug toxicology and clinical laboratory testing. "With this
transaction, Concentra's patients, physicians and employer clients will gain
access to Quest's industry-leading menu of innovative workplace drug and
clinical lab diagnostic information services," said Steve Rusckowski,
President and Chief Executive Officer of Quest. "The transaction is also
consistent with Quest's disciplined capital deployment strategy, which
includes generating one to two percent in growth per year through
strategically aligned fold-in acquisitions." Quest expects the transaction to
be neutral to adjusted earnings per share in 2013 and modestly accretive to
earnings per share in 2014. The Full Research Report on Quest Diagnostics Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at
[http://www.wsreports.com/r/full_research_report/0cb6_DGX]

--

Mettler-Toledo International, Inc. Research Report

On May 23, 2013, Mettler-Toledo International Inc. (METTLER TOLEDO) announced
the launch of its online newsroom, which offers a central location for
industry and media experts to discover what's new at the worldwide supplier of
precision instruments and other enabling technologies. "The newsroom is
helping METTLER TOLEDO bring helpful content to its customers and industries
using social- and multi-media tools alongside its more traditional
communications vehicles," said Marie-Louise Hupert, METTLER TOLEDO's e-Program
Manager. According to the Company, visitors can search archives and decide how
they want to access METTLER TOLEDO literature based on individual preferences.
Media professionals can also access news via a custom search or catalogue
entries organized by product and industry. Ms. Hupert added, "Our goal with
the streamlined access point is to make their lives easier." The Full Research
Report on Mettler-Toledo International, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at [http://www.wsreports.com/r/full_research_report/a364_MTD]

--

Gilead Sciences, Inc. Research Report

According to a Bloomberg report dated June 3, 2013, Hepatitis C research has
currently turned into one of the fastest-developing areas in medicine.
Hepatitis C is an infectious disease that can scar the liver and afflicts
about 170 million people worldwide. New to the Hepatitis C market, Gilead
Sciences, Inc. (Gilead) filed for regulatory clearance for a drug known as
sofosbuvir in April 2013. According to average estimates compiled by
Bloomberg, the pill may reach sales of almost $4 billion in 2015 and $6.3
billion in 2016. The Company's stock has more than doubled in the past year on
optimism about the pill. Bloomberg also reported that Hepatitis C drugs like
sofosbuvir may spawn compulsory generics in countries that can't afford them.
As per Mark Schoenebaum, an analyst at ISI Group in New York, the sofosbuvir
drug may cost as much as $100,000 per patient. The Foster City,
California-based company gained the drug with its $11.1 billion acquisition of
Pharmasset Inc. in year 2012. The Full Research Report on Gilead Sciences,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at
[http://www.wsreports.com/r/full_research_report/9696_GILD]

--

TearLab Corporation Research Report

On May 13, 2013, TearLab Corp. (TearLab) reported its consolidated financial
results for the Q1 2013. The Company reported revenues of $2.5 million,
reflecting a significant increase of 486.5% YoY. The Company's net loss was
approximately $8.6 million, or $0.30 per share, compared to a net loss of $9.1
million or $0.44 per share in Q1 2012. "We started 2013 with strong system
orders and a solid launch of our new Masters program," said Elias Vamvakas,
TearLab's Chief Executive Officer. "While our revenue growth highlights our
continuing success in building a recurring revenue base, like in previous
quarters, our strong sales performance was not fully reflected in our Q1-2013
financial results due to the traditional lag between access program contract
signing and product shipment, and to our current system manufacturing
back-order position. Moving forward, driven by the success of our sales and
marketing programs, and by strong showings at key events like ASCRS, we expect
to see this positive momentum continue through the year." The Full Research
Report on TearLab Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at
[http://www.wsreports.com/r/full_research_report/53d7_TEAR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.